Intercure Ltd. earns a Neutral rating with 3/5 conviction, reflecting a 39.5 composite that lacks sufficient breadth for a more constructive stance. Regulatory is the strongest pillar at 55, supported by Israel’s 70-point jurisdiction posture and an 80 enforcement subscore. Fundamentals contribute 50, as strong top-line expansion is offset by weak profitability and a stretched financial condition. Editorial contributes 30, with no newsroom or brief activity to strengthen the signal. Market contributes only 15 because reported trading volume provides no liquidity support. The resulting profile combines credible jurisdictional standing with limited market confirmation and material financial pressure.
Revenue increased 23.9% year over year, producing a 73.9 growth subscore, but gross margin remained only 16.7% and the gross-margin subscore stood at 27.8. Operating margin was reported at zero, while net income remained negative by approximately 32.1 million and EBITDA was negative by roughly 55.3 million. A cash-burn ratio near one and a 15 cash-runway subscore reinforce the stretched classification; positive revenue momentum does not counter the bottom-line loss or negative EBITDA. Filing cadence is also thin. The latest primary regulatory filing was dated June 22, 2026, with no regulatory events recorded during the latest 90 days and two across 180 days, resulting in a 25 cadence subscore. These observations draw on primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage.
The clearest catalyst sits within the regulatory pillar. Israel’s favorable jurisdiction score and the absence of enforcement hits preserve the company’s strongest analytical foundation, while the low cadence score leaves room for measurable improvement. A fresh sequence of primary regulatory filings that documents operating progress, financial performance, and corporate developments would increase transparency and reinforce the regulatory contribution. That improvement carries greater rating relevance than editorial visibility because regulatory already leads the pillar set and has identifiable support from jurisdiction and enforcement. The single most important forward-looking signal to watch is a sustained acceleration in filing cadence after the June 2026 filing.
Bullish and Bearish Analyst Opinions for InterCure (INCR)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for InterCure (INCR), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Bullish and bearish analyst opinions for InterCure Ltd. (INCR)
Bullish view. InterCure Ltd. is the largest medical-cannabis distributor in Israel with steady script volume, and bulls treat it as the closest thing to a regulated pharma-cannabis pure-play.
Bearish view. Bearish coverage flags concentration in one market, currency volatility, and dependence on Israeli health-fund reimbursement policy.
5-year weekly price history, intraday quotes, and 52-week range for INCR are maintained by Cannabis Investor News and refreshed throughout the trading day.